Author Interviews, Cannabis, JAMA, Mental Health Research / 22.11.2024

MedicalResearch.com Interview with: Belén Blasco PhD Student in Neuroscience - MD Psychiatry Clinical and Translational Sciences (CaTS) Lab Integrated Program in Neuroscience McGill University | Douglas Research Centre Montreal, Canada MedicalResearch.com: What is the background for this study? Response: Our research is centered on uncovering the early brain changes that might contribute to psychosis development. Using innovative brain imaging techniques, we aimed to measure synapsis in individuals with early psychotic symptoms or who are considered at high clinical risk. Synapses are the crucial points of connection between neurons, allowing communication across the brain. A key aspect of our study was to understand how lifestyle factors, like cannabis use, might impact these brain changes, particularly since cannabis consumption has been associated with an increased risk of developing psychosis in young people. (more…)
Alzheimer's - Dementia, Author Interviews, JAMA, Mediterranean Diet, Mental Health Research / 08.05.2023

MedicalResearch.com Interview with: Yuan Changzheng ScD, MSc, B.M. Research Professor Doctoral supervisor, School of Medicine Zhejiang University School of Public Health Adjunct assistant professor Harvard T.H. Chan School of Public Health   MedicalResearch.com: What is the background for this study? Response: The prevention of all-cause dementia is important as it poses substantial burdens on healthcare systems and threatens the well-being of older adults, and lack of effective treatments makes its prevention crucial. The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet is a hybrid of the Mediterranean diet and the DASH diet, and it emphasizes natural plant-based foods, limited intake of certain animal foods and foods high in saturated fat and encourages consumption of berries and green leafy vegetables rich in vitamins and antioxidants. The MIND diet has previously been associated with lower risk of Alzheimer's disease and slower cognitive decline but few studies have examined its association with all-cause dementia or AD with inconclusive results. (more…)
Author Interviews, Gastrointestinal Disease, Mental Health Research / 08.02.2023

MedicalResearch.com Interview with: Yuan, Zhongshang PhD Department of Biostatistics School of Public Health Shandong University Jinan, Shandong, China What is the background for this study? Response: Comorbidities and genetic correlations between gastrointestinal tract diseases and psychiatric disorders have been widely reported, with the gut-brain axis (GBA) hypothesized as a potential biological basis. However, it is unclear the degree to which the shared genetic determinants contribute to these associations underlying GBA. (more…)
Addiction, Author Interviews, JAMA, Mental Health Research, Race/Ethnic Diversity, University of Pennsylvania / 15.12.2022

MedicalResearch.com Interview with: Rebecca Arden Harris, MD, MSc Assistant Professor of Family Medicine and Community Health at the Hospital of the University of Pennsylvania Senior Fellow, Leonard Davis Institute of Health Economics Perelman School of Medicine, University of Pennsylvania MedicalResearch.com: What is the background for this study? Response: The impact of the nationwide overdose epidemic on Black women has received little attention from policy-makers, researchers, or the press. MedicalResearch.com: What are the main findings? Response:  Over the 7-year study period, preventable overdose deaths among Black women resulted in nearly 0.75 million years of life lost (YLL). Women aged 25-34 have suffered a rising proportion of this burden. (more…)
Author Interviews, JAMA, Methamphetamine, NIH, Race/Ethnic Diversity / 24.09.2021

MedicalResearch.com Interview with: Beth Han, M.D., Ph.D., M.P.H. Epidemiologist, Science Policy Branch of the National Institute on Drug Abuse (NIDA), National Institutes of Health MedicalResearch.com: What is the background for this study? Response: In the U.S., overdose deaths involving psychostimulants with abuse potential other than cocaine (i.e. largely methamphetamine), increased dramatically during the past decade. Psychostimulant-involved overdose deaths also often involved opioids (50% in 2017). However, it was still undetermined how trends in methamphetamine use among vulnerable populations and specific patterns of use [e.g. methamphetamine use with or without other substances, frequent methamphetamine use, methamphetamine use disorder (MUD), and injection] may contribute to greater risk for overdose mortality. Moreover, understanding characteristics that are associated with methamphetamine use, frequent use, MUD, and injection is of value in guiding strategies to address the root causes for the recent surge in methamphetamine overdose deaths. (more…)
Author Interviews, JAMA, Mental Health Research / 28.02.2020

MedicalResearch.com Interview with: Dr. Aristotle Voineskos MD, PhD, FRCPC Director, Slaight Family Centre for Youth in Transition and Head, Kimel Family Translational Imaging-Genetics Laboratory Campbell Family Mental Health Research Institute CAMH University of Toronto MedicalResearch.com: What is the background for this study? Response: Uncontrolled studies in humans have shown conflicting results regarding effects of antipsychotic medications on brain structure. Recent studies in animals (e.g. rats and non-human primates) show that these medications may be associated with brain volume loss. To date, our knowledge of the effects of antipsychotic medications on brain structure in humans have been limited by the lack of a double-blind, randomized, placebo-controlled trial with brain imaging. Ours is the first such study. It is considered unethical to do such a study in people with schizophrenia, because of the life-saving benefits of these medications in this illness. However, in people with depression also experiencing psychosis, it was possible to do such a study once people experienced remission from their illness. (more…)
Author Interviews, Cost of Health Care, JAMA, Mental Health Research / 06.06.2019

MedicalResearch.com Interview with: Hefei Wen, PhD Assistant Professor, Department of Health Management & Policy University of Kentucky College of Public Health  MedicalResearch.com: What is the background for this study? Response: Medicaid is the principal payer of behavioral health services in the U.S. and expected to play an increasing role in financing behavioral health services following Medicaid expansions under the ACA. (more…)
Author Interviews, Depression, Genetic Research, JAMA / 19.04.2019

MedicalResearch.com Interview with: Dr Kimberley Kendall MBBCh Wellcome Trust Clinical Research Fellow Professor James Walters MRC Centre for Neuropsychiatric Genetics and Genomics Professor, Division of Psychological Medicine and Clinical Neurosciences Cardiff University   MedicalResearch.com: What is the background for this study? Response: Copy number variants (CNVs) are the deletion or duplication of large sections of DNA. Large, rare CNVs have been shown to increase the risk of neurodevelopmental disorders including autism spectrum disorder (ASD), intellectual disability (ID), attention deficit/hyperactivity disorder (ADHD) and schizophrenia. However, the impact of these CNVs on risk of depression was unclear from the existing literature. (more…)
Author Interviews, Diabetes, Genetic Research, JAMA, Mental Health Research, Schizophrenia / 03.04.2019

MedicalResearch.com Interview with: Prof Sabine Bahn MD PhD MRCPsych FRSB Cambridge Centre for Neuropsychiatric Research Jakub Tomasik, PhD Department of Chemical Engineering and Biotechnology University of Cambridge   MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Schizophrenia patients are at increased risk of impaired glucose metabolism, yet the comorbidity between the two conditions cannot be fully explained by known risk factors such as obesity, smoking, stress or antipsychotic medication. Previous family and genome-wide studies have suggested that the co-occurrence between schizophrenia and impaired glucose metabolism might be due to shared genetic factors, as exemplified by increased risk of diabetes in first-degree relatives of schizophrenia patients, but the biological mechanisms underlying this association remain unknown. We examined the association between insulin resistance, schizophrenia polygenic risk and response to treatment in 58 drug-naive schizophrenia patients and 58 matched healthy individuals while controlling for a range of demographic (age, gender, body mass index), lifestyle (smoking, alcohol and cannabis use) and clinical (psychopathology scores, treatment drug) factors. We found that insulin resistance, a key feature contributing to the development of type 2 diabetes, significantly correlated with schizophrenia polygenic risk score in patients, with higher genetic risk of schizophrenia associated with increased insulin resistance. Furthermore, we found that patients with higher insulin resistance were more likely to switch medication during the first year of treatment, which implies lower clinical response.  (more…)
Author Interviews, Environmental Risks, JAMA, Mental Health Research, Pediatrics / 28.03.2019

MedicalResearch.com Interview with: “air pollution, beijing” by 大杨 is licensed under CC BY 2.0Joanne B. Newbury, PhD ESRC Postdoctoral Fellow King’s College London Social, Genetic & Developmental Psychiatry Centre Institute of Psychiatry, Psychology & Neuroscience London, United Kingdom MedicalResearch.com: What is the background for this study? Response: Urban living is one of the most well-established risk factors for adult psychotic disorders such as schizophrenia. However, less is known about the role of the urban environment in subclinical psychotic experiences in childhood and adolescence, such as hearing voices and extreme paranoia. These early psychotic experiences are a developmental risk factor for adult psychotic disorders and a range of other serious mental health problems such as depression and anxiety. It is therefore important that we understand what factors might contribute to the development of early psychotic experiences so that we might be able to intervene and prevent their onset and progression. In a cohort of over 2000 UK-born children (The Environmental Risk Longitudinal Twin Study), we have previously shown that subclinical psychotic experiences are also around twice as common among children and teenagers raised in urban versus rural settings. We have also shown that this appears to be partly explained by social features in urban neighbourhoods such as higher crime levels and lower levels of social cohesion. However, no studies have examined the potential link between air pollution and psychotic experiences. This is despite air pollution being a major health problem worldwide (particularly in cities), and despite emerging evidence linking air pollution to the brain.  (more…)
Author Interviews, Cannabis, JAMA, Mental Health Research, OBGYNE / 28.03.2019

MedicalResearch.com Interview with: Jeremy Fine B.A. in Philosophy, Neuroscience, and Psychology Washington University in St. Louis, Class of 201 MedicalResearch.com: What is the background for this study? What are the main findings? Response: Alongside increasingly permissive marijuana use attitudes and laws, the prevalence of marijuana use among pregnant mothers has increased substantially (by 75% between 2002 and 2016), with some evidence that pregnant women may be using cannabis to combat pregnancy-related nausea. Our data came from the Adolescent Brain Cognitive Development (ABCD) Study, which included over 4,000 subjects with data on maternal marijuana use during pregnancy. Our main finding was that the children of mothers who used marijuana after learning they were pregnant had a small but significant increase in risk for psychosis in their future. (more…)
Author Interviews, Duke, JAMA, Mental Health Research, Pediatrics, Toxin Research / 23.01.2019

MedicalResearch.com Interview with: Aaron Reuben, MEM Department of Psychology and Neuroscience Duke University, Durham, North Carolina MedicalResearch.com: What is the background for this study? What are the main findings? (1)  Study members with greater lead exposure in childhood tended to endorse more psychiatric symptoms when assessed for psychiatric disorders in adulthood (between 18 and 38 years of age).
  1. These individuals tended to report more internalizing (e.g., depression, anxiety) and thought disorder (e.g., OCD, schizophrenia, mania) symptoms.
  2. Compared to other findings from this sample, the associations reported in this article are similar to those reported for lead and IQ, and are stronger than those reported for lead and criminal offending.
    1. Informants who knew Study members well reported higher levels of difficult adult personality traits among Study members with greater lead exposure in childhood.
    2. Specifically, Study members with greater blood lead levels at age 11 were rated as more neurotic, less agreeable, and less conscientious by 38 years of age.
    3. These personality traits have been previously linked to a number of poor life outcomes, including greater psychopathology, worse physical health, less job satisfaction, and troubled interpersonal relationships
  3. Psychiatric problems related to lead exposure could be detected as early as 11 years of age. In the 1980’s, parents and teachers of children with higher blood-lead levels had described them as displaying more antisocial behavior, hyperactivity, and negative emotions (e.g., sadness, anxiety).
(more…)